3. Rampinelli C, Calloni SF, Minotti M, et al. Spectrum of early lung cancer presentation in low-dose screening CT: a pictorial review. Insights Imaging, 2016, 7(3): 449-459.
6. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e93S-e120S.
[7]
7. Rezaeetalab F, Aryana K, Attaran D, et al. The role of octreotate scan in discrimination of solitary pulmonary nodule. World J Nucl Med, 2014, 13(1): 46-49.
10. Bekci TT, Senol T, Maden E. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), α-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules. J Int Med Res, 2009, 37(2): 438-445.
[11]
11. Wang H, Zhang X, Liu X, et al. Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer. J Cancer Res Ther, 2016, 12(1): 355-358.
[12]
12. Pang L, Wang J, Jiang Y, et al. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy inpatients with non-small cell lung cancer. Exp Ther Med, 2013, 6(2): 355-360.
[13]
13. Chen F, Wang XY, Han XH, et al. Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease. Int J Clin Exp Med, 2015, 8(7): 11295-11300.
[14]
14. Seemann MD, Beinert T, Fürst H, et al. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer, 1999, 26(3): 149-155.
[15]
15. Patz EF Jr, Campa MJ, Gottlin EB, et al. Biomarkers to help guide management of patients with pulmonary nodules. Am J Respir Crit Care Med, 2013, 188(4): 461-465.
[16]
16. Wang R, Wang GQ, Zhang N, et al. Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer. Biomed Res Int, 2013: 195692.
18. Gould MK, Ananth L, Barnett PG, et al. A clinical model to estimate the pretest probability of lung cancer in pmients with solitary pulmonary nodules. Chest, 2007, 131(2): 383-388.
